USA-EU AI MedTech: Pure Global on the New 'PCCP' Regulation Trap

This week, we dive into the groundbreaking joint guidance on AI/ML medical devices recently released by US and EU regulators. This new framework for Predetermined Change Control Plans (PCCPs) promises to accelerate innovation by allowing pre-approved software updates. It's a game-changer for any company operating in the AI MedTech space. But beneath this promising development lies a complex web of requirements that can trap even the most prepared companies. We explore a recent case where a German AI device manufacturer faced a market withdrawal, despite having an approved change plan. Their story is a critical lesson in the operational realities of this new regulatory landscape, revealing how a minor deviation can lead to major compliance failures. Key Takeaways: - What exactly is a Predetermined Change Control Plan (PCCP) and why is it essential for AI devices? - How does the new US-EU harmonized guidance change the game for global market access? - Where are the hidden ambiguities in the new rules that could halt your sales? - Why did a German AI company face a market withdrawal despite having an approved PCCP? - What level of detail is now required in your technical dossier to stay compliant? - How should you design your post-market surveillance plan to support your PCCP? - Is your Quality Management System truly prepared for these new operational demands? Contact us at [email protected] or visit https://pureglobal.com/ or https://pureglobal.ai/ for FREE AI tools and our free medical device database.